These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25310645)

  • 1. Prices paid for adult and paediatric antiretroviral treatment by low- and middle-income countries in 2012: high, low or just right?
    Perriëns JH; Habiyambere V; Dongmo-Nguimfack B; Hirnschall G
    Antivir Ther; 2014; 19 Suppl 3():39-47. PubMed ID: 25310645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey.
    Fortunak JM; de Souza RO; Kulkarni AA; King CL; Ellison T; Miranda LS
    Antivir Ther; 2014; 19 Suppl 3(0 3):15-29. PubMed ID: 25310430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries.
    Waning B; Diedrichsen E; Moon S
    J Int AIDS Soc; 2010 Sep; 13():35. PubMed ID: 20840741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery and development of antiretroviral agents.
    Lange JM; Ananworanich J
    Antivir Ther; 2014; 19 Suppl 3():5-14. PubMed ID: 25310317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production of antiretroviral drugs in middle- and low-income countries.
    Pinheiro Edos S; Brüning K; Macedo MF; Siani AC
    Antivir Ther; 2014; 19 Suppl 3():49-55. PubMed ID: 25310755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market.
    Nakakeeto ON; Elliott BV
    Global Health; 2013 Feb; 9():6. PubMed ID: 23410145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.
    Nunn AS; Fonseca EM; Bastos FI; Gruskin S; Salomon JA
    PLoS Med; 2007 Nov; 4(11):e305. PubMed ID: 18001145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries.
    Orsi F; d'almeida C
    Curr Opin HIV AIDS; 2010 May; 5(3):237-41. PubMed ID: 20539080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examining the production costs of antiretroviral drugs.
    Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
    AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intellectual property rights, market competition and access to affordable antiretrovirals.
    Pascual F
    Antivir Ther; 2014; 19 Suppl 3():57-67. PubMed ID: 25309984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The AIDS response catalysing economic and social transformation: the importance of local pharmaceutical production.
    Sidibé M
    Antivir Ther; 2014; 19 Suppl 3():3-4. PubMed ID: 25310132
    [No Abstract]   [Full Text] [Related]  

  • 12. Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?
    Meiners C; Sagaon-Teyssier L; Hasenclever L; Moatti JP
    PLoS One; 2011; 6(8):e23478. PubMed ID: 21858138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. World Trade Organization still threatens supply of affordable AIDS drugs.
    Hagmann M
    Bull World Health Organ; 2002; 80(9):762-3. PubMed ID: 12378300
    [No Abstract]   [Full Text] [Related]  

  • 14. Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America.
    Wirtz VJ; Santa-Ana-Tellez Y; Trout CH; Kaplan WA
    Health Policy Plan; 2012 Dec; 27(8):638-48. PubMed ID: 22367770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?
    Beck EJ; Mandalia S; DongmoNguimfack B; Pinheiro E; 't Hoen E; Boulet P; Stover J; Gupta A; Juneja S; Habiyambere V; Ghys P; Nunez C
    Glob Health Action; 2019; 12(1):1586317. PubMed ID: 30983547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand.
    Ford N; Wilson D; Costa Chaves G; Lotrowska M; Kijtiwatchakul K
    AIDS; 2007 Jul; 21 Suppl 4():S21-9. PubMed ID: 17620749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shortening the decade-long gap between adult and paediatric drug formulations: a new framework based on the HIV experience in low- and middle-income countries.
    Penazzato M; Lewis L; Watkins M; Prabhu V; Pascual F; Auton M; Kreft W; Morin S; Vicari M; Lee J; Jamieson D; Siberry GK
    J Int AIDS Soc; 2018 Feb; 21 Suppl 1(Suppl Suppl 1):. PubMed ID: 29485727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can the generic antiretroviral industry support access to a universal antiretroviral regimen?
    Amole CD; Middlecote C; Prabhu VR; Kumarasamy N
    Curr Opin HIV AIDS; 2017 Jul; 12(4):390-397. PubMed ID: 28441147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settings.
    Vitoria M; Ford N; Doherty M; Flexner C
    Antivir Ther; 2014; 19 Suppl 3():31-7. PubMed ID: 25310534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.
    Danzon PM; Mulcahy AW; Towse AK
    Health Econ; 2015 Feb; 24(2):238-52. PubMed ID: 24293058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.